학술논문

Thallium- 201.sup.SPECT assessment in the detection of recurrences of treated gliomas and ependymomas
Document Type
Academic Journal
Source
Clinical and Translational Oncology. Oct, 2006, Vol. 8 Issue 10, p750, 5 p.
Subject
Language
English
ISSN
1699-048X
Abstract
Introduction The aim of this study was to establish the value of thalium- .sup.201 single-photon emission computed tomography [(.sup.201]Tl-SPECT) in the detection of recurrences in the follow-up of patients with treated primary neuroepithelial tumours. Material and methods Sixty-three 201.sup.Tl-SPECT were performed in 36 patients with glioma (12 males, mean age of 46+-13 years). All patients underwent surgery and adjuvant radiotherapy (and some of them received chemotherapy). All patients were submitted to morphological neuroimaging techniques as well (and .sup.201 Tl-SPECT). Mean follow-up was 18.3+-14.6 months. Gold standard was based on clinical follow-up, therapeutical decisions (at least 4 months after 201.sup.Tl-SPECT) and imaging features. Results Sensitivity and specificity of 201.sup.Tl-SPECT to detect glioma recurrences were 90% and 100% respectively and 93% accuracy. Sensitivity and specificity for high grade tumours, were 100% respectively. Due to 4 false negatives, sensitivity and specificity for low grade gliomas were 78% and 100%. In the positive 201.sup.Tl-SPECT group of patients overall survival was 13.64% at the end of the study. The negative 201.sup.Tl-SPECT group had 84.62% overall survival at the end of the study (p=0.0003). Conclusions [.sup.201]Tl-SPECT is a valuable and noninvasive diagnostic procedure to detect recurrence or progression disease for treated gliomas and ependymomas. 201.sup.Tl-SPECT has a good correlation with short term prognosis with excellent diagnostic accuracy.